Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Balaji Amines Limited (BALAMINES.NS)
Hyderabad, IN
Balaji Amines Limited, an Indian company, specializes in the production and global distribution of methylamines, ethylamines, their associated derivatives, alongside a diverse portfolio of specialty chemicals and pharmaceutical excipients. The firm's business activities span three primary divisions: Amines & Speciality Chemicals, its Hotel operations, and CFL Lamp manufacturing. Within its chemical segment, Balaji Amines produces a wide range of amines, including monomethylamine, dimethylamine, trimethylamine, monoethylamine, diethylamine, triethylamine, and dimethyl/diethyl amino ethanol. Its specialty chemicals encompass compounds like N-methyl pyrrolidone, morpholine, 2-pyrrolidone, N-ethyl-2-pyrrolidone, gamma-butyrolactone, dimethylformamide, and acetonitrile. Additionally, the company provides derivatives such as di-methyl acetamide, various amine hydrochlorides (di-methyl, tri-methyl, di-ethyl, tri-ethyl), di-methyl urea, and choline chloride. For the pharmaceutical industry, it supplies excipients like poly vinyl pyrrolidone. These chemical products cater to a broad array of sectors, including pharmaceutical, agrochemical, paint and resin, animal feed, oil and gas, rubber cleaning, dye and textile, and water treatment industries. Beyond its chemical endeavors, the company also owns and manages Balaji Sarovar, a hotel property located in Solapur, Maharashtra, and is involved in the manufacturing and sale of CFL lamps. Balaji Amines maintains a significant international presence, exporting its goods to markets across the United States, Europe, China, Turkey, Korea, Malaysia, Kuwait, and other global regions. The company was founded in 1988 and is headquartered in Hyderabad, India.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +19.99% | +7.22% | +43.57% | +50.44% | +32.11% | +44.82% | +20.50% | -32.09% | -32.53% | +699.51% | +5,612.17% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 1 | 0 |
| Buy | 0 | 0 |
| Hold | 0 | 0 |
| Sell | 1 | +1 |
| Strong Sell | 1 | 0 |
-
Revenue growth Chemicals - Specialty: +4.7%+2.0% Q1'26: +11.9% (vs Q1'25)
-
EPS growth Chemicals - Specialty: +13.2%+6.2% Q1'26: +61.7% (vs Q1'25)
-
FCF margin FCF growth · Chemicals - Specialty: +44.1%+5.7% Q1'26: -41.1% (vs Q1'25)
-
EBIT margin Chemicals - Specialty: +8.8%+14.7% ★ Q1'26: +20.3% (vs Q1'25)
-
ROIC Chemicals - Specialty: +5.6%+7.6% ★ Q1'26: +12.0% (vs Q1'25)
-
Share dilution Chemicals - Specialty: +0.1%-0.1% ★ Q1'26: -2.9% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Chemicals - Specialty: 0.18×0.50× ★ Q1'26: 0.35× (vs Q1'25)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Mar 2015 actual |
Mar 2016 actual |
Mar 2017 actual |
Mar 2018 actual |
Mar 2019 actual |
Mar 2020 actual |
Mar 2021 actual |
Mar 2022 actual |
Mar 2023 actual |
Mar 2024 actual |
Mar 2025 actual |
Mar 2026 1 Rev. Ana. 1 EPS Ana. |
Mar 2027 1 Rev. Ana. 2 EPS Ana. |
Mar 2028 1 Rev. Ana. 2 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
6.19B
est: 6.24B (-0.8%)
|
6.43B
est: 6.74B (-4.5%)
|
6.70B
est: 7.16B (-6.3%)
|
8.64B
est: 8.77B (-1.5%)
|
9.43B
est: 9.86B (-4.4%)
|
9.36B
est: 9.29B (+0.7%)
|
13.11B
est: 12.73B (+3.0%)
|
23.20B
est: 20.53B (+13.0%)
|
23.38B
est: 24.82B (-5.8%)
|
16.08B
est: 16.27B (-1.1%)
|
13.97B
est: 14.19B (-1.5%)
|
13.53B
13.53B – 13.53B
-4.6% YoY
|
15.75B
15.75B – 15.75B
+16.4% YoY
|
19.96B
19.96B – 19.96B
+26.7% YoY
|
| EBITDA |
1.06B
est: 1.55B (-31.5%)
|
1.25B
est: 1.67B (-25.0%)
|
1.52B
est: 1.78B (-15.0%)
|
1.86B
est: 2.19B (-15.1%)
|
1.95B
est: 2.24B (-12.7%)
|
1.86B
est: 2.30B (-19.3%)
|
3.79B
est: 1.74B (+117.5%)
|
6.36B
est: 2.05B (+210.4%)
|
6.24B
est: 2.25B (+177.3%)
|
3.53B
est: 2.56B (+38.1%)
|
2.65B
est: 3.52B (-24.6%)
|
3.36B
3.36B – 3.36B
-4.6% YoY
|
3.91B
3.91B – 3.91B
+16.4% YoY
|
4.95B
4.95B – 4.95B
+26.7% YoY
|
| EBIT |
859.43M
est: 1.39B (-38.1%)
|
1.08B
est: 1.50B (-27.8%)
|
1.37B
est: 1.60B (-14.6%)
|
1.73B
est: 1.62B (+6.3%)
|
1.76B
est: 1.96B (-10.3%)
|
1.54B
est: 1.59B (-3.1%)
|
3.45B
est: 1.65B (+108.7%)
|
5.95B
est: 1.94B (+206.8%)
|
5.68B
est: 2.13B (+166.6%)
|
3.08B
est: 2.42B (+27.2%)
|
2.17B
est: 3.16B (-31.4%)
|
3.01B
3.01B – 3.01B
-4.6% YoY
|
3.51B
3.51B – 3.51B
+16.4% YoY
|
4.45B
4.45B – 4.45B
+26.7% YoY
|
| Net Income |
331.97M
est: 338.34M (-1.9%)
|
576.13M
est: 372.05M (+54.9%)
|
823.52M
est: 941.88M (-12.6%)
|
1.13B
est: 1.33B (-14.9%)
|
1.17B
est: 1.36B (-13.9%)
|
1.05B
est: 1.09B (-3.5%)
|
2.38B
est: 1.19B (+100.7%)
|
3.68B
est: 1.39B (+164.2%)
|
3.26B
est: 1.53B (+112.5%)
|
2.05B
est: 1.74B (+17.7%)
|
1.58B
est: 1.61B (-2.3%)
|
1.42B
1.42B – 1.42B
-11.8% YoY
|
1.20B
857.68M – 1.53B
-15.9% YoY
|
2.10B
1.80B – 2.39B
+75.3% YoY
|
| SGA |
388.86M
est: 325.47M (+19.5%)
|
453.59M
est: 351.51M (+29.0%)
|
619.07M
est: 373.38M (+65.8%)
|
774.73M
est: 460.33M (+68.3%)
|
801.89M
est: 348.73M (+129.9%)
|
793.09M
est: 204.04M (+288.7%)
|
961.70M
est: 246.76M (+289.7%)
|
968.94M
est: 289.88M (+234.3%)
|
855.05M
est: 318.42M (+168.5%)
|
833.24M
est: 361.65M (+130.4%)
|
802.16M
est: 740.31M (+8.4%)
|
706.03M
706.03M – 706.03M
-4.6% YoY
|
821.86M
821.86M – 821.86M
+16.4% YoY
|
1.04B
1.04B – 1.04B
+26.7% YoY
|
| EPS |
10.25
est: 10.44 (-1.8%)
|
17.78
est: 11.48 (+54.9%)
|
25.42
est: 28.84 (-11.9%)
|
34.93
est: 40.70 (-14.2%)
|
36.14
est: 37.29 (-3.1%)
|
32.34
est: 36.23 (-10.7%)
|
73.51
est: 63.30 (+16.1%)
|
113.71
est: 111.59 (+1.9%)
|
100.47
est: 138.82 (-27.6%)
|
63.22
est: 63.79 (-0.9%)
|
48.60
est: 49.75 (-2.3%)
|
43.90
43.90 – 43.90
-11.8% YoY
|
36.90
26.46 – 47.34
-15.9% YoY
|
64.70
55.63 – 73.77
+75.3% YoY
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-14 | A- | 4/5 | 4/5 | 4/5 | 5/5 | 2/5 | 2/5 | 3/5 |
| 2026-05-13 | C | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-05-12 | C | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-05-11 | C | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-05-08 | C | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-05-07 | C | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-05-06 | C | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-05-05 | C | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-05-04 | C | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-04-30 | C | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-04-29 | C | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-04-28 | C | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-04-27 | C | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-04-24 | C | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-04-23 | C | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-04-22 | C | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-04-21 | C | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-04-20 | C | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-04-17 | C | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-04-16 | C | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | Vanguard FTSE All-World ex-US Small-Cap ETF VSS | 0.01% | 835.1K | 0.06% |
| 2 | Vanguard FTSE Emerging Markets All Cap Index ETF VEE.TO | 0.00% | 52.7K | 0.26% |
| 3 | Vanguard FTSE Emerging Markets Shares ETF VGE.AX | 0.00% | 23.3K | 0.48% |
| 4 | Vanguard FTSE Emerging Markets ETF VWO | 0.00% | 2.60M | 0.06% |
| 5 | Vanguard ESG International Stock ETF VSGX | 0.00% | 42.9K | 0.10% |
| 6 | Vanguard Total International Stock ETF VXUS | 0.00% | 2.77M | 0.05% |
| 7 | Vanguard Total World Stock ETF VT | 0.00% | 218.6K | 0.06% |
| 8 | Vanguard FTSE Global All Cap ex Canada Index ETF VXC.TO | 0.00% | 4.2K | 0.22% |
| 9 | Vanguard All-Equity ETF Portfolio VEQT.TO | 0.00% | 12.6K | 0.22% |
| 10 | Vanguard Growth ETF Portfolio VGRO.TO | 0.00% | 6.8K | 0.22% |
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Ande Prathap Reddy | Executive Chairman | 90M | male |
| Ande Srinivas Reddy | Whole-Time Director & Chief Financial Officer | 68M | male |
| Dundurapu Ram Reddy | MD & Whole Time Director | 68M | male |
| Nomula Rajeshwar Reddy | Whole-time Director | 7M | male |
| Abhijeet S. Kothadiya | Company Secretary & Compliance Officer | — | male |
| Varsha Guntuk | Manager of Human Resource | — | female |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for BALAMINES.NS
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
